Follow last change Aug 2015 re-read 9 days ago

EF5

also known as NSC#684681 · 18F-EF5 · fluorine F 18 EF5

Investigated by: National Cancer Institute (NCI) · David M. Brizel, MD · Duke University · Gynecologic Oncology Group · Mark Dewhirst · National Institutes of Health (NIH)
+2 more
· Stanford University · University Health Network, Toronto

Trials 12

today NCT01123005 · Ph 1 NCT01055678 · Ph 0 NCT00110032 · Ph 1 NCT00107445 · Ph 2 NCT00087191 · not/applicable NCT00049231 · not/applicable NCT00049140 · Ph 2 NCT02154399 · Ph 2 NCT00041028 · Ph 2 NCT00896961 · not/applicable NCT00004261 · Ph 1 NCT00003282 · Ph 1

199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT01055678	Jan 2010 → Dec 2011	breast cancer	Mark Dewhirst	Withdrawn	No outcome recorded
Phase 14 trials
Phase 1	NCT01123005	Dec 2010 → Aug 2015	neoplasm	Stanford University	Terminated	No outcome recorded
Phase 1	NCT00110032	Jun 2005 → Jan 2007	adult anaplastic ependymoma, adult brain ependymoma, adult brainstem glioma, adult central nervous system germ cell tumor +22	National Cancer Institute (NCI)	Terminated	No outcome recorded
Phase 1	NCT00004261	Dec 1999 → Jun 2002	breast cancer, cervical cancer, head and neck cancer, prostate cancer +1	University Health Network, Toronto	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT00003282	Mar 1998 → May 2005	cancer of unknown primary site	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 24 trials
Phase 2	NCT00107445	Feb → Sep 2005	cervical carcinoma, endometrial carcinoma, malignant epithelial tumor of ovary, peritoneal carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00049140	Aug 2002 → Oct 2004	head and neck cancer	David M. Brizel, MD	Completed	No outcome recorded
Phase 2	NCT02154399	May 2002 → Sep 2007	non-small cell lung carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00041028	May 2002 → Sep 2007	lung cancer	Duke University	Completed	No outcome recorded
Phase not applicable3 trials
—	NCT00087191	May 2004 → Jan 2006	appendix carcinoma, carcinoid tumor, exocrine pancreatic carcinoma, extrahepatic bile duct carcinoma +16	National Cancer Institute (NCI)	Terminated	No outcome recorded
—	NCT00049231	Jun 2003 → Aug 2005	cervical cancer	Gynecologic Oncology Group	Completed	No outcome recorded
—	NCT00896961	Aug 2001 → Sep 2007	lip and oral cavity squamous cell carcinoma, soft tissue sarcoma	National Cancer Institute (NCI)	Terminated	No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

Field	Value	Cited text
Known as	EF5	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00896961 ↗ 11 NCT00041028 ↗ NCT00110032 ↗ NCT00087191 ↗ NCT00004261 ↗ NCT00107445 ↗ NCT00003282 ↗ NCT01123005 ↗ NCT02154399 ↗ NCT00049140 ↗ NCT00049231 ↗ Show 1 more source
Known as	18F-EF5	“Patients receive fluorine F 18 EF5 (\^18F-EF5) IV followed by whole brain and whole body positron emission tomography (PET) scanning OR whole body PET scanning only.” NCT00110032 ↗
Known as	fluorine F 18 EF5	“Patients receive fluorine F 18 EF5 (\^18F-EF5) IV followed by whole brain and whole body positron emission tomography (PET) scanning OR whole body PET scanning only.” NCT00110032 ↗
Known as	NSC#684681	“A Phase I Trial of the Hypoxia Detection Agent EF5 (NSC 684681) in Patients With Cervix and Breast and Prostate Carcinomas, and High Grade Soft Tissue Sarcomas” NCT00004261 ↗ 1 “Evaluation of Hypoxia by EF5 (NSC#684681) Binding in Cervix Cancer” NCT00049231 ↗
Modality	Diagnostic / imaging agent	“Diagnostic procedures using the drug EF5 to detect the presence of oxygen in tumor cells” NCT00003282 ↗
Route	Intravenous	“EF5 IV over 1-2 hours” NCT00003282 ↗